Ocular Therapeutix Inc (NASDAQ:OCUL) was the recipient of a large growth in short interest in the month of November. As of November 29th, there was short interest totalling 6,880,000 shares, a growth of 6.5% from the November 14th total of 6,460,000 shares. Currently, 16.6% of the shares of the company are sold short. Based on an average daily volume of 524,600 shares, the short-interest ratio is currently 13.1 days.

Shares of NASDAQ:OCUL traded up $0.01 during trading on Friday, reaching $4.06. The company had a trading volume of 319,141 shares, compared to its average volume of 638,003. The firm’s fifty day moving average is $3.45 and its 200 day moving average is $3.93. Ocular Therapeutix has a twelve month low of $2.35 and a twelve month high of $5.64. The company has a current ratio of 6.33, a quick ratio of 6.25 and a debt-to-equity ratio of 5.07.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. The company had revenue of $0.83 million during the quarter, compared to analyst estimates of $1.09 million. Ocular Therapeutix had a negative net margin of 3,141.58% and a negative return on equity of 383.58%. As a group, analysts anticipate that Ocular Therapeutix will post -1.72 earnings per share for the current fiscal year.

A number of research analysts have issued reports on OCUL shares. Piper Jaffray Companies reduced their target price on shares of Ocular Therapeutix from $8.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and set a $6.00 target price (down from $9.00) on shares of Ocular Therapeutix in a research note on Friday, November 15th. Finally, Zacks Investment Research raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $8.67.

Large investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in shares of Ocular Therapeutix in the 3rd quarter worth approximately $31,000. SG Americas Securities LLC bought a new stake in shares of Ocular Therapeutix in the 3rd quarter worth approximately $32,000. Creative Planning bought a new stake in shares of Ocular Therapeutix in the 2nd quarter worth approximately $52,000. Clear Harbor Asset Management LLC bought a new stake in shares of Ocular Therapeutix in the 3rd quarter worth approximately $38,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Ocular Therapeutix in the 3rd quarter worth approximately $44,000. 48.01% of the stock is owned by institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Featured Article: How does a security become overbought?

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.